Scientific Sessions

Inflammation and immune system dysregulation play central roles in the development and progression of various heart diseases, including atherosclerosis, myocarditis, heart failure, and post-infarction remodeling. Chronic low-grade inflammation contributes to endothelial dysfunction, plaque formation, and destabilization in coronary arteries, increasing the risk of myocardial infarction and stroke. Activation of innate and adaptive immune responses, involving cytokines, chemokines, and immune cells, exacerbates myocardial injury, fibrosis, and remodeling, influencing both structural and functional cardiac outcomes. Understanding these processes has revealed novel therapeutic targets and pathways for cardiovascular intervention.

Recent research highlights the interplay between systemic inflammation, autoimmune conditions, and cardiovascular risk. Biomarkers such as high-sensitivity C-reactive protein (hs-CRP), interleukins, and circulating immune cells provide insights into disease activity and prognosis. Therapeutic strategies targeting immune pathways, including anti-inflammatory drugs, monoclonal antibodies, and immunomodulatory agents, are being explored to mitigate cardiac injury and prevent adverse outcomes. Additionally, integration of molecular immunology with imaging and genomics allows precise monitoring of inflammatory activity within the myocardium and vasculature. By elucidating the immune and inflammatory mechanisms underlying heart disease, clinicians and researchers are developing more effective, targeted therapies that improve patient outcomes and reduce the burden of cardiovascular morbidity and mortality.